A solid-phase PEGylation strategy for protein therapeutics using a potent FGF21 analog

Biomaterials

Volumn 35, Issue 19, 2014, Pages 5206-5215

  Song, Lintao ^a,b   Zhu, Yanlin ^a   Wang, Huiyan ^c   Belov, Artur A ^d   Niu, Jianlou ^a   Shi, Lu ^a   Xie, Yaoyao ^a   Ye, Chaohui ^a   Li, Xiaokun ^a,b   Huang, Zhifeng ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b JILIN AGRICULTURAL UNIVERSITY   (China)

^c JILIN MEDICAL COLLEGE   (China)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biostability; Human fibroblast growth factor 21; Mutation; Solid phase PEGylation; Type 2 diabetes

Indexed keywords

AMINO ACIDS; BIOACTIVITY;

BIOSTABILITY; HUMAN FIBROBLAST GROWTH FACTOR 21; MUTATION; PEGYLATION; TYPE-2 DIABETES;

PROTEINS;

CYSTEINE; FIBROBLAST GROWTH FACTOR 21; MACROGOL; MALEIMIDE; NICKEL; RECOMBINANT CYTOKINE; FIBROBLAST GROWTH FACTOR; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG HALF LIFE; DRUG POTENCY; DRUG STABILITY; IN VIVO STUDY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SITE DIRECTED MUTAGENESIS; SOLID; SOLID PHASE NICKEL AFFINITY PEGYLATION; SURFACE PROPERTY; 3T3 CELL LINE; ANIMAL; CHEMISTRY; DIABETES MELLITUS, TYPE 2; HUMAN; MALE; RAT; WESTERN BLOTTING;

3T3-L1 CELLS; ANIMALS; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; MICE; POLYETHYLENE GLYCOLS; RATS; RECOMBINANT PROTEINS;

EID: 84898451567     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.023     Document Type: Article

References (46)

1. Baird A., Klagsbrun M. The fibroblast growth factor family. Cancer Cells 1991, 3:239-243.
2. McKeehan W.L., Wang F., Kan M. The heparan sulfate-fibroblast growth factor family: diversity of structure and function. Prog Nucleic Acid Res Mol Biol 1998, 59:135-176.
3. Nishimura T., Nakatake Y., Konishi M., Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 2000, 1492:203-206.
4. Kharitonenkov A., Shiyanova T.L., Koester A., Ford A.M., Micanovic R., Galbreath E.J., et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005, 115:1627-1635.
5. Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M. Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem 2006, 281:15694-15700.
6. Goetz R., Beenken A., Ibrahimi O.A., Kalinina J., Olsen S.K., Eliseenkova A.V., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol 2007, 27:3417-3428.
7. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem 2007, 282:26687-26695.
8. Kharitonenkov A., Shanafelt A.B. Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 2008, 22:37-44.
9. Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001, 414:782-787.
10. Lillioja S., Mott D.M., Spraul M., Ferraro R., Foley J.E., Ravussin E., et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 1993, 329:1988-1992.
11. Weyer C., Funahashi T., Tanaka S., Hotta K., Matsuzawa Y., Pratley R.E., et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001, 86:1930-1935.
12. Kharitonenkov A. FGFs and metabolism. Curr Opin Pharmacol 2009, 9:805-810.
13. Xu J., Lloyd D.J., Hale C., Stanislaus S., Chen M., Sivits G., et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009, 58:250-259.
14. Xu J., Stanislaus S., Chinookoswong N., Lau Y.Y., Hager T., Patel J., et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models-association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 2009, 297:E1105-E1114.
15. Kliewer S.A., Mangelsdorf D.J. Fibroblast growth factor 21: from pharmacology to physiology. Am J Clin Nutr 2010, 91:254S-257S.
16. Kharitonenkov A., Wroblewski V.J., Koester A., Chen Y.F., Clutinger C.K., Tigno X.T., et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 2007, 148:774-781.
17. Badman M.K., Koester A., Flier J.S., Kharitonenkov A., Maratos-Flier E. Fibroblast growth factor 21-deficient mice demonstrate impaired adaptation to ketosis. Endocrinology 2009, 150:4931-4940.
18. Hotta Y., Nakamura H., Konishi M., Murata Y., Takagi H., Matsumura S., et al. Fibroblast growth factor 21 regulates lipolysis in white adipose tissue but is not required for ketogenesis and triglyceride clearance in liver. Endocrinology 2009, 150:4625-4633.
19. Gaich G., Chien J.Y., Fu H., Glass L.C., Deeg M.A., Holland W.L., et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 2013, 18:333-340.
20. Reitman M.L. FGF21 mimetic shows therapeutic promise. Cell Metab 2013, 18:307-309.
21. Harris J.M., Martin N.E., Modi M. Pegylation: a novel process for modifying pharmacokinetics. Clin Pharmacokinet 2001, 40:539-551.
22. Katre N.V., Knauf M.J., Laird W.J. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. Proc Natl Acad Sci U S A 1987, 84:1487-1491.
23. Kitamura K., Takahashi T., Takashina K., Yamaguchi T., Noguchi A., Tsurumi H., et al. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization. Biochem Biophys Res Commun 1990, 171:1387-1394.
24. Lee B.K., Kwon J.S., Kim H.J., Yamamoto S., Lee E.K. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug Chem 2007, 18:1728-1734.
25. Filpula D., Yang K., Basu A., Hassan R., Xiang L., Zhang Z., et al. Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice. Bioconjug Chem 2007, 18:773-784.
26. Hu J., Duppatla V., Harth S., Schmitz W., Sebald W. Site-specific PEGylation of bone morphogenetic protein-2 cysteine analogues. Bioconjug Chem 2010, 21:1762-1772.
27. Jevsevar S., Kunstelj M., Porekar V.G. PEGylation of therapeutic proteins. Biotechnol J 2010, 5:113-128.
28. Pan L.Q., Wang H.B., Lai J., Xu Y.C., Zhang C., Chen S.Q. Site-specific PEGylation of a mutated-cysteine residue and its effect on tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Biomaterials 2013, 34:9115-9123.
29. Kaminskas L.M., Ascher D.B., McLeod V.M., Herold M.J., Le C.P., Sloan E.K., et al. PEGylation of interferon alpha2 improves lymphatic exposure after subcutaneous and intravenous administration and improves antitumour efficacy against lymphatic breast cancer metastases. J Control Release 2013, 168:200-208.
30. Carter P.J. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011, 317:1261-1269.
31. Hecht R., Li Y.S., Sun J., Belouski E., Hall M., Hager T., et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of type 2 diabetes. PLoS One 2012, 7:e49345.
32. Adams A.C., Halstead C.A., Hansen B.C., Irizarry A.R., Martin J.A., Myers S.R., et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS One 2013, 8:e65763.
33. Kharitonenkov A., Beals J.M., Micanovic R., Strifler B.A., Rathnachalam R., Wroblewski V.J., et al. Rational design of a fibroblast growth factor 21-based clinical candidate, LY2405319. PLoS One 2013, 8:e58575.
34. Veniant M.M., Komorowski R., Chen P., Stanislaus S., Winters K., Hager T., et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 2012, 153:4192-4203.
35. Xu J., Bussiere J., Yie J., Sickmier A., An P., Belouski E., et al. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation. Bioconjug Chem 2013, 24:915-925.
36. Zhang J., Li Y. Fibroblast growth factor 21, the endocrine FGF pathway and novel treatments for metabolic syndrome. Drug Discov Today 2013, http://dx.doi.org/10.1016/j.drudis.2013.10.021.
37. Beenken A., Mohammadi M. The structural biology of the FGF19 subfamily. Adv Exp Med Biol 2012, 728:1-24.
38. Wang H., Xiao Y., Fu L., Zhao H., Zhang Y., Wan X., et al. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol 2010, 10:14.
39. Huang Z., Ye C., Liu Z., Wang X., Chen H., Liu Y., et al. Solid-phase N-terminus PEGylation of recombinant human fibroblast growth factor 2 on heparin-sepharose column. Bioconjug Chem 2012, 23:740-750.
40. Ito S., Kinoshita S., Shiraishi N., Nakagawa S., Sekine S., Fujimori T., et al. Molecular cloning and expression analyses of mouse betaklotho, which encodes a novel Klotho family protein. Mech Dev 2000, 98:115-119.
41. Badman M.K., Pissios P., Kennedy A.R., Koukos G., Flier J.S., Maratos-Flier E. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 2007, 5:426-437.
42. Donath M.Y., Shoelson S.E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 2011, 11:98-107.
43. Calle M.C., Fernandez M.L. Inflammation and type 2 diabetes. Diabetes Metab 2012, 38:183-191.
44. Trevaskis J.L., Gawronska-Kozak B., Sutton G.M., McNeil M., Stephens J.M., Smith S.R., et al. Role of adiponectin and inflammation in insulin resistance of Mc3r and Mc4r knockout mice. Obesity (Silver Spring) 2007, 15:2664-2672.
45. Holness C.L., da Silva R.P., Fawcett J., Gordon S., Simmons D.L. Macrosialin, a mouse macrophage-restricted glycoprotein, is a member of the lamp/lgp family. J Biol Chem 1993, 268:9661-9666.
46. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.